Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 23, 2026, 6:48 AM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

NCT00314054
View directory record Official record
Conditions
Hepatitis C, Hepatic Insufficiency
Interventions
HCV-796
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

NCT00402428
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 23, 2026, 6:48 AM EDT
Terminated Phase 1 Interventional

HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

NCT01377909
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
statin
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

NCT00142298
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 23, 2026, 6:48 AM EDT
Completed No phase listed Observational

An Observational Study of Hepatitis C Virus in Pregnancy

NCT01959321
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

NCT03180619
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

NCT04000737
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Sorafenib+YIV-906, Sorafenib+placebo
Drug
Lead sponsor
Yiviva Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Flushing, New York • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PegIFN/RBV, BI201335, BI201335 24W, Bi 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 23, 2026, 6:48 AM EDT
Terminated Phase 4 Interventional Results available

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

NCT03625687
View directory record Official record
Conditions
Respiratory Failure, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 23, 2026, 6:48 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

NCT07096193
View directory record Official record
Conditions
Chronic Hepatitis Delta
Interventions
GS-4321, GS-4321 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
5
States / cities
Anaheim, California • La Jolla, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

NCT01030432
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-650032, Placebo, Peginterferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures

NCT05593211
View directory record Official record
Conditions
Hepatic Disease, Renal Disease
Interventions
Kronos Electrocautery Device
Device
Lead sponsor
Single Pass Inc
Industry
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

NCT00015652
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Aldesleukin, Peginterferon alfa-2b
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional Results available

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

NCT04198584
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VC-CBCS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 23, 2026, 6:48 AM EDT
Completed No phase listed Observational

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis

NCT02400216
View directory record Official record
Conditions
Cirrhosis
Interventions
dual cholate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 6:48 AM EDT
Recruiting Phase 1 Interventional

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852
View directory record Official record
Conditions
Hepatitis B, Chronic Hepatitis B
Interventions
Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1

NCT03245931
View directory record Official record
Conditions
Hepatitis C
Interventions
Qualitative Interview
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional Results available

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

NCT04427202
View directory record Official record
Conditions
HIV, Hepatitis C, Opioid-use Disorder, Injection Drug Use
Interventions
Referral to harm reduction services
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
15 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Carbondale, Illinois • Murphysboro, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 23, 2026, 6:48 AM EDT
Withdrawn Phase 2 Interventional

Study the Relationship Between Obesity and Hepatitis C Replication

NCT01157975
View directory record Official record
Conditions
Hepatitis C
Interventions
Pioglitazone, Prednisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 23, 2026, 6:48 AM EDT